Exalpha Biologicals, Inc.

Accelerating the Pace of Discovery

Product Highlight

Mouse anti-M13 phage coat protein g8p

Antibodies recognising M13 filamentous phage coat proteins are instrumental in the selection and detection of phages expressing specific antibody fragments or peptide sequences at their surface. The monoclonal antibodies manufactured and supplied by Exalpha react with either the pIII (g3p) or pVIII (g8p) proteins of M13 filamentous bacteriophage. All antibodies are available in a purified format. The antibodies are fully validated and are suitable for a wide range of techniques including:

  • ELISA
  • Flow Cytometry
  • Western Blot
  • Immunohistochemistry
  • Immunoprecipitation
For more information, click here for our M13 Bacteriophage information page.

News

Two more of our excellent products have been published by PubMed:

Potential actionable targets in appendiceal cancer detected by immunohistochemistry, fluorescent in situ hybridization, and mutational analysis
Borazanci, E., et al., J. Gastrointest. Oncol., 8, 164-172 (2017)
Using Exalpha SPARC Antibody (Cat. No. X1867P)

Molecular mechanism underlying the pharmacological interactions of the protein kinase C-β inhibitor enzastaurin and erlotinib in non-small cell lung cancer cells
Steen, N.V., et al., Am. J. Cancer Res., 7, 816-830 (2017)
Using Exalpha's FITC labeled anti PY20 Antibody (Cat. No. X1017)

Exalpha Biologicals, Inc.

Progesterone receptor

  • Product Code: X1437M
  • Size: 100 µg
  • Price (USD): $528

Cat #

X1437M		 Quantity:      

Data Sheet

Product Name

Progesterone receptor

Host/Source

Mouse

Clone

hPRa2 + hPRa3

Isotype

IgG

Product Type

Monoclonal Antibody

Reactivity

Human, Horse, Pig

Applications

Western Blot, Immunoprecipitation, Immunohistochemistry (Paraffin & Frozen sections), Immunofluorescense

Purification

Protein A/G Chromatography

Size

100 µg

Price (USD)

$528

Background

Equally recognizes two proteins: 116kDa (triplet) and 81kDa (singlet), identified as the hormone-binding high (B) and low (A) MW forms of human PgR. Expression of PgR has been suggested to reflect a intact estrogen regulatory machinery and therefore, predict better clinical response to endocrine therapy than ER alone. This antibody is excellent for immunohistochemical staining of formalin/paraffin tissues.

Immunogen

Hybridoma produced by the fusion of splenocytes from RBF/DN mice immunized with PgR from a human endometrial carcinoma (EnCa 101) grown in athymic mice and mouse myeloma HL-1 Friendly cells.

Positive Control

T47D or breast carcinoma

Formulation

Provided as solution in phosphate buffered saline with 0.08% sodium azide

Customer Storage

Product should be stored at -20°C. Aliquot to avoid freeze/thaw cycles

Product Image

Image Legend

Immunohistochemical staining using progesterone receptor antibody on formalin fixed, paraffin embedded human breast carcinoma.

Database Links:

SwissProtO00264Human

References

1. Satyaswaroop PG. Development of a preclinical model for hormonal therapy of human endometrial carcinomas. Annals of Medicine, 1993, 25:105-11.

2. Shyamala G; et al. Relationship between 90-kilodalton heat shock protein, estrogen receptor, and progesterone receptor in human mammary tumors. Breast Cancer Research and Treatment, 1993, 26(1):95-100.

3. Satyaswaroop PG; et al. Apparent resistance in human endometrial carcinoma during combination treatment with tamoxifen and progestin may result from desensitization following downregulation of tumor progesterone receptor. Cancer Letters, 1992, 62(2):107-14.

4. Clarke CL; et al. Direct transcriptional regulation of the progesterone receptor by retinoic acid diminishes progestin responsiveness in the breast cancer cell line T-47D. Journal of Biological Chemistry, 1991 Oct 5, 266(28):18969-75.

5. Schneider W; et al. Murine progesterone receptor exists predominantly as the 83-kilodalton 'A' form. Journal of Steroid Biochemistry and Molecular Biology, 1991, 38(3):285-91.

6. Mortel R; et al. Designing a schedule of progestin administration in the control of endometrial carcinoma growth in the nude mouse model. American Journal of Obstetrics and Gynecology, 1990, 162(4):928-34; discussion 934-6.

7. Clarke CL; et al. Progesterone receptor regulation by retinoic acid in the human breast cancer cell line T-47D. Journal of Biological Chemistry, 1990 Jul 25, 265(21):12694-700.

8. Clarke CL. Cell-specific regulation of progesterone receptor in the female reproductive system. Molecular and Cellular Endocrinology, 1990 May 7, 70(3):C29- 33.

9. Satyaswaroop PG; Mortel R. Hormonal treatment of endometrial carcinoma: an overview and new development in biology. Journal of Steroid Biochemistry and Molecular Biology, 1990, 37(6):997-1001.

10. Shyamala G; Schneider W; Schott D. Developmental regulation of murine mammary progesterone receptor gene expression. Endocrinology, 1990 Jun, 126(6):2882-9.

11. Alexander IE; Clarke CL; Shine J; Sutherland RL. Progestin inhibition of progesterone receptor gene expression in human breast cancer cells. Molecular Endocrinology, 1989 Sep, 3(9):1377-86.


12. Feil PD; Clarke CL; Satyaswaroop PG. A polyclonal antiserum against the rabbit progesterone receptor recognizes the human receptor: biochemical characterization. Cell Biochemistry and Function, 1989, 7(2):139-46.

13. Satyaswaroop PG; Zaino RJ; Mortel R. Carcinoma of the endometrium and hormonal receptors. Cancer Treatment and Research, 1989, 49:71-92.

14. Tabibzadeh SS; Satyaswaroop PG. Sex steroid receptors in lymphoid cells of human endometrium. American Journal of Clinical Pathology, 1989, 91(6):656-63.

15. Zaino RJ; Clarke CL; Feil PD; Satyaswaroop PG. Differential distribution of estrogen and progesterone receptors in rabbit uterus detected by dual immunofluorescence. Endocrinology, 1989, 125(5):2728-34.

16. Feil PD; Clarke CL; Satyaswaroop PG. Progesterone receptor structure and protease activity in primary human endometrial carcinoma. Cancer Research, 1988, 48(5):1143-7.

17. Feil PD; Clarke CL; Satyaswaroop PG. Progestin- mediated changes in progesterone receptor forms in the normal human endometrium. Endocrinology, 1988, 123(5):2506-13.

18. Zaino RJ; Clarke CL; Mortel R; Satyaswaroop PG. Heterogeneity of progesterone receptor distribution in human endometrial adenocarcinoma. Cancer Research, 1988, 48(7):1889-95.

19. Clarke CL; Feil PD; Satyaswaroop PG. Progesterone receptor regulation by 17 beta-estradiol in human endometrial carcinoma grown in nude mice. Endocrinology, 1987, 121(5):1642-8.

20. Satyaswaroop PG; Zaino R; Clarke CL; Mortel R. Nude mouse system in the study of tumor biology, treatment strategies and progesterone receptor physiology in human endometrial carcinoma. Journal of Steroid Biochemistry, 1987, 27(1-3):431-8.

21. Satyaswaroop PG; Zaino RJ; Mortel R. Steroid receptors and human endometrial carcinoma: studies in a nude mouse model. Cancer Metastasis Reviews, 1987, 6(3):223-41.

22. Clarke CL; et. al. Endocrinology, 1987, 121:1123-32.

23. Gray GO; Satyaswaroop PG. Biochem Biophys Res Comm, 1988, 157(3):1067-77.